VEGFA and age-related macular degeneration: This administration route is used in the therapy of exudative senile macular degeneration, where anti-vascular endothelial growth factor (VEGF) drugs (e.g., bevacizumab, ranibizumab, and aflibercept) are injected every 30–60 days to reach and maintain a sustained therapeutic concentration [34].